1. Home
  2. RZLT vs LUNG Comparison

RZLT vs LUNG Comparison

Compare RZLT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$1.81

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.54

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RZLT
LUNG
Founded
2010
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
63.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RZLT
LUNG
Price
$1.81
$2.54
Analyst Decision
Strong Buy
Buy
Analyst Count
6
7
Target Price
$12.33
$6.81
AVG Volume (30 Days)
9.7M
1.1M
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.59
52 Week Low
$1.07
$1.31
52 Week High
$11.46
$9.37

Technical Indicators

Market Signals
Indicator
RZLT
LUNG
Relative Strength Index (RSI) 22.97 71.32
Support Level $1.07 $1.96
Resistance Level $11.17 $1.74
Average True Range (ATR) 0.66 0.20
MACD -0.81 0.10
Stochastic Oscillator 7.23 91.13

Price Performance

Historical Comparison
RZLT
LUNG

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: